Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Change in Intangibles (2017 - 2025)

BeOne Medicines (BEIGF) has disclosed Change in Intangibles for 5 consecutive years, with $20.0 million as the latest value for Q2 2025.

  • Quarterly Change in Intangibles changed N/A to $20.0 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $20.0 million through Dec 2025, up 327.9% year-over-year, with the annual reading at $20.0 million for FY2025, 327.9% up from the prior year.
  • Change in Intangibles for Q2 2025 was $20.0 million at BeOne Medicines, up from $4.7 million in the prior quarter.
  • The five-year high for Change in Intangibles was $20.0 million in Q2 2025, with the low at $4.7 million in Q1 2024.
  • Average Change in Intangibles over 3 years is $11.0 million, with a median of $9.7 million recorded in 2023.